Reader TTS

ABSTRACT The c-erbB-2 product is thought to be a unique and useful target for antibody therapy of cancers overexpressing the c-erbB-2 gene. In vitro and in vivo anti-tumour effects of a

humanised antibody against the extracellular domain of the c-erbB-2 gene product, rhu4D5, were examined. Rhu4D5 was less effective than its murine counterpart, mu4D5, for the direct

antiproliferative activity against the c-erbB-2-overexpressing SK-BR-3 cell line. In vivo treatment of severe combined immunodeficient (SCID) mice carrying the c-erbB-2-overexpressing 4-1ST

human gastric carcinoma xenograft with 4hu4D5 revealed that the recombinant protein had potent anti-tumour activity. Furthermore, cytotoxicity of human peripheral blood mononuclear cells

against 4-1ST was significantly augmented with rhu4D5, but not with mu4D5. These results indicate that rhu4D5 might perform better in patients than predicted from preclinical studies. Access

through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal

Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices

may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

SIMILAR CONTENT BEING VIEWED BY OTHERS AN ANTI-CD98 ANTIBODY DISPLAYING PH-DEPENDENT FC-MEDIATED TUMOUR-SPECIFIC ACTIVITY AGAINST MULTIPLE CANCERS IN CD98-HUMANIZED MICE Article 24 November

2022 TWO NOVEL HUMAN ANTI-CD25 ANTIBODIES WITH ANTITUMOR ACTIVITY INVERSELY RELATED TO THEIR AFFINITY AND IN VITRO ACTIVITY Article Open access 25 November 2021 PRECLINICAL EVIDENCE FOR THE

EFFECTIVE USE OF TL-895, A HIGHLY SELECTIVE AND POTENT SECOND-GENERATION BTK INHIBITOR, FOR THE TREATMENT OF B-CELL MALIGNANCIES Article Open access 21 November 2023 AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * Department of Surgery, Tokai University School of Medicine, Kanagawa, Japan Y Tokuda Authors * Y Tokuda View author publications You can also search for this

author inPubMed Google Scholar * Y Ohnishi View author publications You can also search for this author inPubMed Google Scholar * K Shimamura View author publications You can also search for

this author inPubMed Google Scholar * M Iwasawa View author publications You can also search for this author inPubMed Google Scholar * M Yoshimura View author publications You can also

search for this author inPubMed Google Scholar * Y Ueyama View author publications You can also search for this author inPubMed Google Scholar * N Tamaoki View author publications You can

also search for this author inPubMed Google Scholar * T Tajima View author publications You can also search for this author inPubMed Google Scholar * T Mitomi View author publications You

can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Tokuda, Y., Ohnishi, Y., Shimamura, K. _et al._

_In vitro_ and _in vivo_ anti-tumour effects of a humanised monoclonal antibody against c-_erb_B-2 product. _Br J Cancer_ 73, 1362–1365 (1996). https://doi.org/10.1038/bjc.1996.259 Download

citation * Issue Date: 01 June 1996 * DOI: https://doi.org/10.1038/bjc.1996.259 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable

link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative